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Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia
(range 230-62,000/µl) in the 18 patients in whom NPM1 mutation was performed in both PB and BM, respectively. There was complete concordance between PB and BM in detecting FLT3-ITD mutation, 8 had FLT3-ITD detected in both PB and BM while 22 had no mutation detected. In 2 patients FLT3-ITD were detected in PB despite very low WBC counts (400/µl and 170/µl) and no circulating blasts on the smear differentials, with the finding confirmed by the presence of a FLT3-ITD in BM (Table1). Allelic ratios were highly correlated in PB and BM with correlation coefficient 0.92 (95% CI 0.82 to 0.96; p < 0.0001). There was also complete concordance between PB and BM in the 18 patients in whom NPM1 mutations were analyzed in both: 4 had mutations in both PB and BM and 14 were NPM1 wild type in both PB and BM. All of the patients with NPM1 mutations had elevated WBC counts and high percentage of circulating blasts.
Next, we looked at the 227 patients who had FLT3-ITD mutational status evaluated in the PB.
These included the 30 patients described previously who had FLT3-ITD mutation performed in both PB and BM. Of these, 61 patients were positive for FLT3-ITD and the rest were negative, and most of these patients had no corresponding BM study performed concurrently. While the median WBC and absolute blasts were 30,410/µl and 20,500/µl for the 61 patients who were FLT3-ITD positive, and the values were 8,400/µl and 1,900/µl for patients who were negative.
Out of these 61 patients, 13 patients had absolute blast counts less than 2000/µl ( Table 2) . We also looked at the 152 patients who had NPM1 mutational status evaluated in the PB. These included the 18 patients described above. NPM1 mutation was detected in 37 out of the 152 patients. The median WBC and absolute blasts were 30,000/µl and 26,900/µl for the 37 patients who were NPM1 positive, and the values were 18,600/µl and 6,500/µl for patients who were negative. Out of these 37 patients, 13 patients had absolute blast counts less than 2000/µl.
The presence of tumor specific DNA in plasma of patients with solid tumors has been reported in numerous previous studies, including breast, lung, colorectal and prostate cancers(5, 6).
Conventional cytogenetic, FISH or molecular techniques using either PB or BM samples have been commonly used for detecting possible genetic and molecular abnormalities in various hematological malignancies. In patients with chronic myelogenous leukemia(7) or acute promyelocytic leukemia (8) , cytogenetics and molecular studies for BCR-ABl or PML-RARA are frequently done using PB, and are sometimes preferred over BM to monitor disease status during treatment. It is also more convenient for the patients since this doesn't involve more invasive bone marrow aspiration and biopsy. Jilani et al. reported that FLT3-ITD were more readily detected in DNA extracted from PB plasma than from BM, reflecting PB plasma is enriched in leukemic cell DNA compared with normal DNA(9). Hussein et al studied the feasibility of using PB in place of BM for cytogenetic studies during the evaluation of hematologic malignancies (42 out of 242 were AML patients)(10). They found cytogenetic studies were successfully performed using PB in 58% of the cases, and it was 76% in AML patients. On multivariate analysis, only progenitor cells/blast and BM chromosome abnormality predicted success in obtaining metaphases from PB. The success rate improved as the number of circulating progenitor cells increased.
Despite the small patient numbers, our study suggests high sensitivity and specificity of PB for detection of FLT3-ITD and NPM1 mutations when the absolute blast count is > 2000/µl. Given the greater rapidity with which PB can be obtained, PB might be used in lieu of BM for detection of FLT3-ITD and NPM1 mutations in these patients at the time of initial diagnosis or following treatment response. In some cases FLT3-ITD can be detected in PB even when the absolute blast count is < 2000/µl, although further work is needed to examine concordance with BM and clinical significance in such cases.
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